Aptahem is active within biotechnology. The company conducts research and development of aptamer-based pharmaceuticals for the treatment of acute conditions caused by sepsis, blockage of blood vessels, stroke, and heart failure. Through early treatment, the pharmaceutical is intended to prevent damage to organs and tissue. A large part of the research is carried out in collaboration with partners within the industry. The company was founded in 2014 and is based in Malmö.

Quotes for Aptahem AB

Right Now

+/-
-0.06
%
-2,69%
Latest
2.17
High
2.31
Low
2.17
Volume
50 248
Turnover (SEK)
111 942
Value (MSEK)
103,9

Board

CEO

  • Mikael Lindstam

Chairman Of The Board

  • Kjell Stenberg

Board

  • Cristina Glad
  • Johan Lindh
  • Mikael Lindstam
  • Theresa Comiskey Olsen

Videos

Largest Owners

Name Capital % Votes % Date
Ivar Nordqvist 27,53 27,53 2019-02-19
Nordnet Pensionsförsäkring 12,21 12,21 2019-12-31
Avanza Pension 5,34 5,34 2019-12-31
AB Svedala Finans 2,40 2,40 2019-12-31
Adel Hanna 1,29 1,29 2019-12-31
Johan Magnus Lindh 1,13 1,13 2019-12-31
Gunvald Berger 1,13 1,13 2019-12-31
Tina Kerstin Veronica Persson 1,10 1,10 2019-12-31
Susanna Sundin 0,86 0,86 2019-12-31
Tommy Schantli 0,67 0,67 2019-12-31
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

Key Numbers

*Compiled data from Millistream